Overview of Brain Barrier Drug Delivery in Alzheimer s Disease

Mohammad Khodayarnejad¹ zahra zaghari²

1) Researcher
2) Ph.D. Physiology, University of Science and Research. Tehran. Iran

Publication : 3.rd International Congress of Science, Engineering and Technology - Hamburg(germanconf.com)
Abstract :
Alzheimer s disease is a chronic neurological disorder associated with the accumulation of beta-amyloid protein and neurofibrillary intracellular tangles in the brain. Non-medical therapy is mainly aimed at improving the quality of life or maintaining patients cognitive abilities and daily activity. So far, there are six drugs prescribed by the Food and Drug Administration to treat Alzheimer s. However, these drugs can only temporarily relieve the symptoms of the disease, and none of them have demonstrated the ability to cure or halt the progression of the disease. Medications are always associated with side effects such as nausea, diarrhea and vomiting. Alzheimer s disease is a major challenge in the pharmaceutical sciences. In this review, we summarize current knowledge about the pathophysiology of Alzheimer s disease. Then, we review the structural and biological properties of the blood-brain barrier. We describe the most promising pharmaceutical systems introduced in recent years. These include polymer nanoparticles, liposomes, metal nanoparticles, and cyclodextrins. Overall, our goal is to provide ideas and clues for designing effective drug delivery systems to penetrate the blood-brain barrier to treat Alzheimer s disease.
Keywords : brain delivery; blood-brain barrier; central nervous system; nanomaterials; Alzheimer’s disease.